Skip to main content
Erschienen in: Current Cardiovascular Risk Reports 1/2010

01.01.2010

High-Density Lipoprotein Proteomics: Identifying New Drug Targets and Biomarkers by Understanding Functionality

verfasst von: Scott Gordon, Anita Durairaj, Jason L. Lu, W. Sean Davidson

Erschienen in: Current Cardiovascular Risk Reports | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Recent proteomics studies on human plasma high-density lipoprotein (HDL) have discovered up to 50 individual protein constituents. Many of these have known functions that vary surprisingly from the lipid transport roles commonly thought to mediate HDL’s ability to protect from coronary artery disease. Given newly discovered roles in inflammation, protease inhibition, complement regulation, and innate immunity, many have begun to view HDL as a broad collection of distinct particle subfamilies, each distinguished by unique protein compositions and functions. Herein we review recent applications of high-resolution proteomics to HDL and summarize evidence supporting the idea of HDL functional subspeciation. These studies have set the stage for a more complete understanding of the molecular basis of HDL functional heterogeneity and hold promise for the identification of new biomarkers that can predict disease or evaluate the success of clinical interventions.
Literatur
1.
Zurück zum Zitat Adorni MP, Zimetti F, Billheimer JT, et al.: The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res 2007, 48:2453–2462.CrossRefPubMed Adorni MP, Zimetti F, Billheimer JT, et al.: The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res 2007, 48:2453–2462.CrossRefPubMed
2.
Zurück zum Zitat Gu X, Trigatti B, Xu S, et al.: The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain. J Biol Chem 1998, 273:26338–26348.CrossRefPubMed Gu X, Trigatti B, Xu S, et al.: The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain. J Biol Chem 1998, 273:26338–26348.CrossRefPubMed
3.
Zurück zum Zitat Moore RE, Navab M, Millar JS, et al.: Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res 2005, 97:763–771.CrossRefPubMed Moore RE, Navab M, Millar JS, et al.: Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res 2005, 97:763–771.CrossRefPubMed
4.
Zurück zum Zitat Navab M, Hama SY, Anantharamaiah GM, et al.: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein. Steps 2 and 3. J Lipid Res 2000, 41:1495–1508.PubMed Navab M, Hama SY, Anantharamaiah GM, et al.: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein. Steps 2 and 3. J Lipid Res 2000, 41:1495–1508.PubMed
5.
Zurück zum Zitat Barter PJ, Rye KA: High density lipoproteins and coronary heart disease. Atherosclerosis 1996, 121:1–12.CrossRefPubMed Barter PJ, Rye KA: High density lipoproteins and coronary heart disease. Atherosclerosis 1996, 121:1–12.CrossRefPubMed
6.
Zurück zum Zitat Navab M, Imes SS, Hama SY, et al.: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991, 88:2039–2046.CrossRefPubMed Navab M, Imes SS, Hama SY, et al.: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991, 88:2039–2046.CrossRefPubMed
7.
Zurück zum Zitat Puranik R, Bao S, Nobecourt E, et al.: Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis 2008, 196:240–247.CrossRefPubMed Puranik R, Bao S, Nobecourt E, et al.: Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis 2008, 196:240–247.CrossRefPubMed
8.
Zurück zum Zitat Rye KA, Bursill CA, Lambert G, et al.: The metabolism and anti-atherogenic properties of HDL. J Lipid Res 2009, 50(Suppl):S195–S200CrossRefPubMed Rye KA, Bursill CA, Lambert G, et al.: The metabolism and anti-atherogenic properties of HDL. J Lipid Res 2009, 50(Suppl):S195–S200CrossRefPubMed
9.
Zurück zum Zitat Concha MI, Smith VJ, Castro K, et al.: Apolipoproteins A-I and A-II are potentially important effectors of innate immunity in the teleost fish Cyprinus carpio. Eur J Biochem 2004, 271:2984–2990.CrossRefPubMed Concha MI, Smith VJ, Castro K, et al.: Apolipoproteins A-I and A-II are potentially important effectors of innate immunity in the teleost fish Cyprinus carpio. Eur J Biochem 2004, 271:2984–2990.CrossRefPubMed
10.
Zurück zum Zitat Cruz D, Watson AD, Miller CS, et al.: Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest 2008, 118:2917–2928.CrossRefPubMed Cruz D, Watson AD, Miller CS, et al.: Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest 2008, 118:2917–2928.CrossRefPubMed
11.
Zurück zum Zitat • Heinecke JW: The HDL proteome: a marker–and perhaps mediator–of coronary artery disease. J Lipid Res 2009, 50(Suppl):S167–S171. This excellent summary of HDL proteomics focuses on the work of the Heinecke laboratory.CrossRefPubMed • Heinecke JW: The HDL proteome: a marker–and perhaps mediator–of coronary artery disease. J Lipid Res 2009, 50(Suppl):S167–S171. This excellent summary of HDL proteomics focuses on the work of the Heinecke laboratory.CrossRefPubMed
12.
Zurück zum Zitat • Hoofnagle AN, Heinecke JW: Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins. J Lipid Res 2009, 50:1967–1975. This article presents another good review of HDL proteomics.CrossRefPubMed • Hoofnagle AN, Heinecke JW: Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins. J Lipid Res 2009, 50:1967–1975. This article presents another good review of HDL proteomics.CrossRefPubMed
13.
Zurück zum Zitat Reilly MP, Tall AR: HDL proteomics: pot of gold or Pandora’s box? J Clin Invest 2007, 117:595–598.CrossRefPubMed Reilly MP, Tall AR: HDL proteomics: pot of gold or Pandora’s box? J Clin Invest 2007, 117:595–598.CrossRefPubMed
14.
Zurück zum Zitat Kontush A, Chantepie S, Chapman MJ: Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003, 23:1881–1888.CrossRefPubMed Kontush A, Chantepie S, Chapman MJ: Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003, 23:1881–1888.CrossRefPubMed
15.
Zurück zum Zitat Cheung MC, Albers JJ: Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem 1984, 259:12201–12209.PubMed Cheung MC, Albers JJ: Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem 1984, 259:12201–12209.PubMed
16.
Zurück zum Zitat Asztalos BF, Sloop CH, Wong L, Roheim PS: Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta 1993, 1169:291–300.PubMed Asztalos BF, Sloop CH, Wong L, Roheim PS: Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta 1993, 1169:291–300.PubMed
17.
Zurück zum Zitat Warnick GR, Nauck M, Rifai N: Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem 2001, 47:1579–1596.PubMed Warnick GR, Nauck M, Rifai N: Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem 2001, 47:1579–1596.PubMed
18.
Zurück zum Zitat Duong PT, Weibel GL, Lund-Katz S, et al.: Characterization and properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I. J Lipid Res 2008, 49:1006–1014.CrossRefPubMed Duong PT, Weibel GL, Lund-Katz S, et al.: Characterization and properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I. J Lipid Res 2008, 49:1006–1014.CrossRefPubMed
19.
Zurück zum Zitat Haginaka J, Yamaguchi Y, Kunitomo M: Anion-exchange high-performance liquid chromatography assays of plasma lipoproteins and modified low-density lipoproteins using a ProtEx-DEAE column. J Chromatogr B Biomed Sci Appl 2001, 751:161–167.CrossRefPubMed Haginaka J, Yamaguchi Y, Kunitomo M: Anion-exchange high-performance liquid chromatography assays of plasma lipoproteins and modified low-density lipoproteins using a ProtEx-DEAE column. J Chromatogr B Biomed Sci Appl 2001, 751:161–167.CrossRefPubMed
20.
Zurück zum Zitat van’t Hooft F, Havel RJ: Metabolism of apolipoprotein E in plasma high density lipoproteins from normal and cholesterol-fed rats. J Biol Chem 1982, 257:10996–11001. van’t Hooft F, Havel RJ: Metabolism of apolipoprotein E in plasma high density lipoproteins from normal and cholesterol-fed rats. J Biol Chem 1982, 257:10996–11001.
21.
Zurück zum Zitat • Stahlman M, Davidsson P, Kanmert I, et al.: Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J Lipid Res 2008, 49:481–490. This article presents a comparison of different methods for floating lipoproteins during density ultracentrifugation that shows the potential for artifacts in the KBr procedure.CrossRefPubMed • Stahlman M, Davidsson P, Kanmert I, et al.: Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J Lipid Res 2008, 49:481–490. This article presents a comparison of different methods for floating lipoproteins during density ultracentrifugation that shows the potential for artifacts in the KBr procedure.CrossRefPubMed
22.
Zurück zum Zitat Karlsson H, Leanderson P, Tagesson C, Lindahl M: Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5:551–565.CrossRefPubMed Karlsson H, Leanderson P, Tagesson C, Lindahl M: Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5:551–565.CrossRefPubMed
23.
Zurück zum Zitat Santos RD, Schaefer EJ, Asztalos BF, et al.: Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. J Lipid Res 2008, 49:349–357.CrossRefPubMed Santos RD, Schaefer EJ, Asztalos BF, et al.: Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. J Lipid Res 2008, 49:349–357.CrossRefPubMed
24.
Zurück zum Zitat Movva R, Rader DJ: Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008, 54:788–800.CrossRefPubMed Movva R, Rader DJ: Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008, 54:788–800.CrossRefPubMed
25.
Zurück zum Zitat Davidson WS, Jonas A, Clayton DF, George JM: Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 1998, 273:9443–9449.CrossRefPubMed Davidson WS, Jonas A, Clayton DF, George JM: Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 1998, 273:9443–9449.CrossRefPubMed
26.
Zurück zum Zitat Canas B, Lopez-Ferrer D, Ramos-Fernandez A, et al.: Mass spectrometry technologies for proteomics. Brief Funct Genomic Proteomic 2006, 4:295–320.CrossRefPubMed Canas B, Lopez-Ferrer D, Ramos-Fernandez A, et al.: Mass spectrometry technologies for proteomics. Brief Funct Genomic Proteomic 2006, 4:295–320.CrossRefPubMed
27.
Zurück zum Zitat Karlsson H, Leanderson P, Tagesson C, Lindahl M: Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5:1431–1445.CrossRefPubMed Karlsson H, Leanderson P, Tagesson C, Lindahl M: Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5:1431–1445.CrossRefPubMed
28.
Zurück zum Zitat Subramaniyam D, Glader P, von Wachenfeldt K, et al.: C-36 peptide, a degradation product of alpha1-antitrypsin, modulates human monocyte activation through LPS signaling pathways. Int J Biochem Cell Biol 2006, 38:563–575.CrossRefPubMed Subramaniyam D, Glader P, von Wachenfeldt K, et al.: C-36 peptide, a degradation product of alpha1-antitrypsin, modulates human monocyte activation through LPS signaling pathways. Int J Biochem Cell Biol 2006, 38:563–575.CrossRefPubMed
29.
Zurück zum Zitat Heller M, Stalder D, Schlappritzi E, et al.: A. Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins. Proteomics 2005, 5:2619–2630.CrossRefPubMed Heller M, Stalder D, Schlappritzi E, et al.: A. Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins. Proteomics 2005, 5:2619–2630.CrossRefPubMed
30.
Zurück zum Zitat Rezaee F, Casetta B, Levels JH, et al.: Proteomic analysis of high-density lipoprotein. Proteomics 2006, 6:721–730.CrossRefPubMed Rezaee F, Casetta B, Levels JH, et al.: Proteomic analysis of high-density lipoprotein. Proteomics 2006, 6:721–730.CrossRefPubMed
31.
Zurück zum Zitat Hortin GL, Shen RF, Martin BM, Remaley AT: Diverse range of small peptides associated with high-density lipoprotein. Biochem Biophys Res Commun 2006, 340:909–915.CrossRefPubMed Hortin GL, Shen RF, Martin BM, Remaley AT: Diverse range of small peptides associated with high-density lipoprotein. Biochem Biophys Res Commun 2006, 340:909–915.CrossRefPubMed
32.
Zurück zum Zitat •• Vaisar T, Pennathur S, Green PS, et al.: Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007, 117:746–756. Liquid chromatography ESI-MS/MS was used to identify proteins from ultracentrifugally isolated HDL of healthy control subjects and subjects with established CAD. A total of 48 proteins were identified. Using a novel peptide counting strategy, it was found that HDL 3 from CAD patients was selectively enriched in apoE and other proteins that may play a role in macrophage biology, lipid metabolism, and the inflammatory response.CrossRefPubMed •• Vaisar T, Pennathur S, Green PS, et al.: Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007, 117:746–756. Liquid chromatography ESI-MS/MS was used to identify proteins from ultracentrifugally isolated HDL of healthy control subjects and subjects with established CAD. A total of 48 proteins were identified. Using a novel peptide counting strategy, it was found that HDL 3 from CAD patients was selectively enriched in apoE and other proteins that may play a role in macrophage biology, lipid metabolism, and the inflammatory response.CrossRefPubMed
33.
Zurück zum Zitat •• Green PS, Vaisar T, Pennathur S, et al.: Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 2008, 118:1259–1267. This is the first study to utilize HDL proteomics as a measure of the efficacy of lipid-lowering therapies.CrossRefPubMed •• Green PS, Vaisar T, Pennathur S, et al.: Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 2008, 118:1259–1267. This is the first study to utilize HDL proteomics as a measure of the efficacy of lipid-lowering therapies.CrossRefPubMed
34.
Zurück zum Zitat •• Davidson WS, Silva RA, Chantepie S, et al.: Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009, 29:870–876. This study mapped the HDL proteome across five density subfractions indicating clearly distinct protein profiles. This study also associated specific apolipoproteins with antioxidative function.CrossRefPubMed •• Davidson WS, Silva RA, Chantepie S, et al.: Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009, 29:870–876. This study mapped the HDL proteome across five density subfractions indicating clearly distinct protein profiles. This study also associated specific apolipoproteins with antioxidative function.CrossRefPubMed
35.
Zurück zum Zitat Boyle KE, Phillips MC, Lund-Katz S: Kinetics and mechanism of exchange of apolipoprotein C-III molecules from very low density lipoprotein particles. Biochim Biophys Acta 1999, 1430:302–312.PubMed Boyle KE, Phillips MC, Lund-Katz S: Kinetics and mechanism of exchange of apolipoprotein C-III molecules from very low density lipoprotein particles. Biochim Biophys Acta 1999, 1430:302–312.PubMed
36.
Zurück zum Zitat Qiu X, Mistry A, Ammirati MJ, et al.: Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol 2007, 14:106–113.CrossRefPubMed Qiu X, Mistry A, Ammirati MJ, et al.: Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol 2007, 14:106–113.CrossRefPubMed
37.
Zurück zum Zitat Asztalos BF, Schaefer EJ: High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 2003, 91:12E–17E.CrossRefPubMed Asztalos BF, Schaefer EJ: High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 2003, 91:12E–17E.CrossRefPubMed
38.
Zurück zum Zitat Jonas A: Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. Biochim Biophys Acta 1991, 1084:205–220.PubMed Jonas A: Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. Biochim Biophys Acta 1991, 1084:205–220.PubMed
39.
Zurück zum Zitat Wang X, Driscoll DM, Morton RE: Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F. J Biol Chem 1999, 274:1814–1820.CrossRefPubMed Wang X, Driscoll DM, Morton RE: Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F. J Biol Chem 1999, 274:1814–1820.CrossRefPubMed
40.
Zurück zum Zitat Jahangiri A, Rader DJ, Marchadier D, et al.: Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J Lipid Res 2005, 46:896–903.CrossRefPubMed Jahangiri A, Rader DJ, Marchadier D, et al.: Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J Lipid Res 2005, 46:896–903.CrossRefPubMed
41.
Zurück zum Zitat Rifkin MR: Identification of the trypanocidal factor in normal human serum: high density lipoprotein. Proc Natl Acad Sci U S A 1978, 75:3450–3454.CrossRefPubMed Rifkin MR: Identification of the trypanocidal factor in normal human serum: high density lipoprotein. Proc Natl Acad Sci U S A 1978, 75:3450–3454.CrossRefPubMed
42.
Zurück zum Zitat Nielsen MJ, Nielsen LB, Moestrup SK: High-density lipoprotein and innate immunity. Future Lipidol 2006, 1:729–734.CrossRef Nielsen MJ, Nielsen LB, Moestrup SK: High-density lipoprotein and innate immunity. Future Lipidol 2006, 1:729–734.CrossRef
43.
Zurück zum Zitat Shiflett AM, Bishop JR, Pahwa A, Hajduk SL: Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J Biol Chem 2005, 280:32578–32585.CrossRefPubMed Shiflett AM, Bishop JR, Pahwa A, Hajduk SL: Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J Biol Chem 2005, 280:32578–32585.CrossRefPubMed
44.
Zurück zum Zitat Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000, 101:207–213.PubMed Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000, 101:207–213.PubMed
45.
Zurück zum Zitat Ansell BJ, Navab M, Hama S, et al.: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003, 108:2751–2756.CrossRefPubMed Ansell BJ, Navab M, Hama S, et al.: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003, 108:2751–2756.CrossRefPubMed
Metadaten
Titel
High-Density Lipoprotein Proteomics: Identifying New Drug Targets and Biomarkers by Understanding Functionality
verfasst von
Scott Gordon
Anita Durairaj
Jason L. Lu
W. Sean Davidson
Publikationsdatum
01.01.2010
Verlag
Current Science Inc.
Erschienen in
Current Cardiovascular Risk Reports / Ausgabe 1/2010
Print ISSN: 1932-9520
Elektronische ISSN: 1932-9563
DOI
https://doi.org/10.1007/s12170-009-0069-9

Weitere Artikel der Ausgabe 1/2010

Current Cardiovascular Risk Reports 1/2010 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.